The differentiation-promoting potential of a cytostatic fluoro-pyranosyl adriamycin analog (FAD 104).

Abstract

Acute toxicity to the hematopoietic cell renewal system is a critical side effect of most anticancer agents. Here we compared the effects of FAD-104 to those of the parent compound adriamycin (ADM) and of epi-adriamycin (epi-ADM) on the growth and differentiation of normal as well as leukemic human myeloid progenitor cells. FAD-104 was less toxic to myeloid colony-forming cells (GM-CFU) than ADM or epi-ADM. In addition, FAD-104 but not ADM induced a clonal down-grading in both normal and leukemic blast cells, and it stimulated the terminal differentiation of myeloid leukemia cells. Therefore, FAD-104 may be useful in the treatment of some forms of myeloid leukemia.

• Authors: I Blazsek, G Mathé, M Comisso, H Kitasato, K Umezawa, H Umezawa
• Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (Biomed Pharmacother) Vol. 43 Issue 4 Pg. 267-70 ( 1989) ISSN: 0753-3322 [Print] France
• PMID: 2790148 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• ME 2303
• Doxorubicin

Topics

• Antineoplastic Agents (toxicity)
• Bone Marrow (pathology)
• Colony-Forming Units Assay
• Doxorubicin (analogs & derivatives, toxicity)
• Hematopoietic Stem Cells (drug effects)
• Humans
• Leukemia, Myeloid, Acute (pathology)